Table 3.
Patient characteristics.
| RA | AS | Total | |
|---|---|---|---|
| n | 36 | 17 | 53 |
| female:male | 31:5 | 3:14 | 34:19 |
| age (mean ± SD) (range), years | 55.9 ± 9.8 (35–83) | 43.6 ± 12.4 (24–72) | 52.0 ± 12.1 (24–83) |
| disease duration (mean ± SEM) (range), years | 9.1 ± 8.3 (1–44) | 7.2 ± 7.0 (1–26) | 8.5 ± 7.9 (1–44) |
| age at diagnosis | 47.0 ± 8.7 (28–62) | 36.4 ± 11.6 (23–50) | 43.5 ± 12.1 (23–62) |
| smoking (current) | 7 | 7 | 14 |
| positive CV history | 8 | 1 | 9 |
| BMI (mean ± SD), kg/m2 | 29.3 ± 3.6 | 31.1 ± 3.8 | 29.9 ± 3.7 |
| obesity (BMI > 30 kg/m2) | 17 | 11 | 28 |
| diabetes mellitus history | 3 | 1 | 4 |
| hypertension history | 17 | 4 | 21 |
| RF positivity, n (%) | 26 (72) | - | - |
| Anti-CCP positivity, n (%) | 21 (58) | - | - |
| DAS28-CRP (baseline) (mean ± SD) | 5.00 ± 0.86 | - | - |
| BASDAI (baseline) (mean ± SD) | - | 5.79 ± 1.19 | - |
| Treatment (ETN, CZP) | 20 ETN, 16 CZP | 17 ETN | 37 ETN, 16 CZP |
Abbreviations: AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BMI, body mass index; CCP, cyclic citrullinated peptide; CV, cardiovascular; CZP, certolizumab pegol; DAS28-CRP, 28-joint disease activity score; ETN, etanercept; RA, rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation.